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Summary 
We have developed a functional screen in yeast to 
identify ligands for receptor tyrosine kinases. Using 
this method, we cloned two Xenopus genes that acti- 
vate the fibroblast growth factor (FGF) receptor. These 
encode novel secreted proteins, designated FRLl and 
FRLP, distantly related to the epidermal growth factor 
and angiogeniruribonuclease families, respectively. 
Both genes activate the FGF receptor in Xenopus oo- 
cytes as well as in yeast. Overexpression induces 
mesoderm and neural-specific genes in Xenopus ex- 
plants; induction is blocked by a dominant negative 
inhibitor of the FGF receptor. FRLl is broadly ex- 
pressed during gastrulation and neurulation, while 
FRL2 is expressed principally in the axial mesoderm 
and brain at later stages. Our results indicate that de- 
spite their lack of similarity with FGF, FRLl and FRL2 
are ligands for the FGF receptor that play distinct roles 
in development. 
Introduction 
Peptide growth factors, mediated by specific cell surface 
receptors, regulate many cell processes, such as growth, 
division, and differentiation. Many of these activate mem- 
bers of a superfamily of receptor tyrosine kinases that con- 
tains an extracellular ligand-binding domain, a transmem- 
brane domain, and a cytoplasmic domain harboring a 
regulated protein tyrosine kinase activity. Upon ligand 
binding to the receptor, the cytoplasmic kinase is acti- 
vated, leading to the activation of the receptor-specific 
intracellular signaling pathways. 
In the past 10 years, many tyrosine kinase receptors 
have been identified. Because the tyrosine kinase do- 
mains of this receptor family are highly conserved, tech- 
niques dependent on sequence similarity can be used to 
identify family members. By contrast, methods for identi- 
fying the ligands for tyrosine kinase receptors have lagged 
behind, and for many cloned receptors, the peptide ligand 
has not yet been identified. For the most part, identification 
of ligands involves biochemical fractionation, which relies 
on having sufficient quantities and sensitive assays; how- 
ever, other methods using receptor affinity have recently 
been introduced (Flanagan and Leder, 1990; Lyman et 
al., 1993; Cheng and Flanagan, 1994). 
To identify potential ligands for orphan tyrosine kinase 
receptors, we have developed a novel yeast screening 
method based on the functional coexpression of a receptor 
and itscorresponding ligand in thesameyeast cell. Recep- 
tor-ligand interactions in principle could take place either 
on a cell surface or in intracellular compartments. In either 
case, the cytoplasmically oriented kinase of the receptor 
would be activated and phosphorylate cytoplasmic pro- 
teins; this activity could be detected by an increase in total 
intracellular tyrosine phosphate. By using this approach, 
it should be possible to screen for the ligand of an orphan 
receptor by coexpressing a cDNA library and the orphan 
receptor in yeast and detecting those colonies with ele- 
vated tyrosine kinaseactivity. Thefactthat higher eukaryo- 
tic genes can be functionally expressed in yeast, and that 
yeast has negligible tyrosine kinase activity, supports the 
feasibility of the approach. 
We show that yeast cells expressing the Xenopus laevis 
fibroblast growth factor (FGF) receptor gene exhibit a large 
increase in tyrosine phosphorylation upon cotransforma- 
tion with the FGF gene. This increase in tyrosine phos- 
phate occurs only if the ligand has a functional signal se- 
quence. We have adapted this procedure to screen a 
Xenopus cDNA library by using a yeast strain expressing 
an FGF receptor. Two genes encoding novel secreted pro- 
teins were identified with the yeast assay and subse- 
quently characterized by other assays. These ligands, 
designated FRLl and FRL2 (for FGF receptor ligands 1 
and 2) are very distantly related to two other proteins: an 
epidermal growth factor (EGF)-related protein, cripto (also 
referred to as teratoma-derived growth factor 1, or Tdgfl), 
and another secreted protein, angiogenin (Ciccodicola et 
al., 1989; Kurachi et al., 1985; Beintema et al., 1988). Our 
results indicate that despite their lack of similarity to the 
primary sequences of the FGF family, FRLl and FRL2 are 
novel ligands for the FGF receptor. Furthermore, these 
ligands seem to play distinct roles in Xenopus development. 
Results 
Detection of FGF Receptor Activation by FGF in yeast 
We tested whether coexpression of a receptor tyrosine 
kinase and its ligand leads to the activation of the kinase in 
Yea54 (Saccharomyces cerevisiae) cells. Three plasmids 
were constructed. The first, pG-FGFR, harbors the Xeno- 
Pus FGF receptor 1 gene (Musci et al., 1990). Thesecond, 
pFGF, contains the Xenopus FGF2 (basic FGF) gene (Ki- 
melman et al., 1988), which does not have an endogen- 
ous Signal sequence. The third, pssFGF, encodes FGF2 
fused downstream to a yeast SUC2 signal sequence (Carl- 
son et al., 1983). All these genes are under the control of 
the GAL7 promoter. 
TO determine whether the receptor tyrosine kinase is 
activated in these strains, these transformants were cul- 
tured in the presence or absence of galactose, and whole- 
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Figure 1. Activation of the FGF Receptor in Yeast by Coexpression 
of the FGF2 Gene 
(A) Phosphotyrosinecontent of endogenousyeast proteins in response 
to expression of FGF and its receptor. Yeast strains transformed with 
the vectors (lanes 1 and 5), pG-FGFR (lanes 2 and 6) pG-FGFR plus 
pFGF (lanes 3 and 7), and pG-FGFR plus pssFGF (lanes 4 and 6) 
were cultured in glucose-containing media (lanes l-4) and in galac- 
tose-containing media (lanes 5-8). Whole-cell extracts were prepared 
by cell disruption with glass beads and were analyzed by immunoblot- 
ting with anti-phosphotyrosine antibody. 
(6) The detection of the FGF receptor activation in yeast cells by colony 
immunoblotting. FGF and the FGF receptorwere coexpressed in yeast 
and analyzed by colony immunoblotting with anti-phosphotyrosine an- 
tibody. The FGF receptor was under the control of the GAL7 promoter 
(G-FGFR) or the ACT7 promoter (A-FGFR). FGF with or without signal 
sequence (ssFGF or FGF) was under the control of the GAL I promoter. 
Yeast strains transformed by the indicated genes were grown on a 
plate. Colonies were transferred to two membranes and cultured on 
a glucose-containing or a galactose-containing plate. 
cell extracts were analyzed by immunoblotting with an- 
ti-phosphotyrosine antibody (Figure 1A). The following 
results were obtained when expression was induced by 
galactose: first, expression of the FGF receptor gene alone 
led to a substantial increase in tyrosine phosphorylation 
of several endogenous proteins; second, the coexpression 
of the FGF receptor and FGF2 lacking a signal sequence 
(pFGF) did not increase phosphorylation above that of the 
FGF receptor alone; and third, coexpression of the FGF 
receptor and FGF2 with a signal sequence (pssFGF) dra- 
matically increased tyrosine phosphorylation. The phos- 
phorylation level was five times higher than the level ob- 
served after expression of the FGF receptor alone. The 
level of FGF2 was unaffected by the presence of the signal 
sequence (data not shown). Since ssFGFs were not de- 
tected in the medium (data not shown), FGF is probably 
localized in intracellular compartments, in the periplasmic 
space, or both. These results indicate that the FGF recep- 
tor is activated by the expression of its corresponding li- 
gand in yeast and that the ligand must be capable of enter- 
ing the secretory pathway for receptor activation to occur. 
Measuring Receptor Activation 
by Colony lmmunoblotting 
We screened large numbers of yeast transformants by 
using colony immunoblotting (Lyons and Nelson, 1984) 
with anti-phosphotyrosine antibody. To test the reliability 
of receptor activation by this method, we used yeast 
strains expressing the FGF2 and the FGF receptor genes 
under the control of the GAL7 promoter. FGF or ssFGF 
was coexpressed with the receptor, and the yeast cells 
were streaked on a glucose-containing plate. Colonies 
were transferred to two nitrocellulose filters; one filter was 
placed on a galactose-containing plate to induce FGF ex- 
pression, and the other was placed on a glucose-containing 
plate as a negative control, and the level of tyrosine phos- 
phorylation in each colony was determined with anti- 
phosphotyrosine antibody. The results confirmed the im- 
munoblotting data in Figure 1A. The expression of the 
FGF receptor led to an increase in the level of tyrosine 
phosphorylation that was substantially augmented when 
ssFGF was coexpressed, but not when FGF lacking a sig- 
nal sequence was coexpressed (Figure 16). 
There was an unsuitably high background from the FGF 
receptor under control of the GAL7 promoter in the ab- 
sence of FGF expression. We therefore tried placing the 
FGF receptor under the control of the ACT7 promoter (ac- 
tin gene; Gallwitz et al., 1981) in an attempt to optimize 
the assay. We found the ACT7 promoter more suitable. It 
gave similar levels of FGF receptor gene expression in 
galactose- and in glucose-containing media, and levels of 
tyrosine phosphorylation were low in the absence of FGF, 
but significantly increased by expression of FGF (Fig- 
ure 16). 
Screening cDNA Libraries with a Yeast Strain 
Expressing the Xenopus FGF Receptor Gene 
The above results suggested that the method could be 
used to identify novel ligandsfortyrosine kinase receptors. 
As a first step, we used the method to identify ligands for 
the FGF receptor. Yeast cells expressing the FGF receptor 
were transformed with two cDNA libraries: one was made 
from mRNA isolated from Xenopus unfertilized eggs and 
gastrula embryos (egg library), and the other was made 
from Xenopus tissue culture (XTC) cells (XTC library). 
The egg and XTC libraries yielded 150,000 and 25,000 
transformants, respectively. In the first screening by 
colony immunoblotting with an anti-phosphotyrosine anti- 
body, 65 and 29 candidates were identified, respectively, 
and by the second screening, nine and two transformants 
were found to be positive (egg and XTC libraries, respec- 
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Table 1. Genes That increase Protein-Tyrosine Phosphorylation in Yeast Ceils Expressing FGF Receptor 
I 
FGF Receptor Frequency 
Gene Dependency Gene Product ’ of Isolation 
FRL 1 + Cripto (EGF-like growth factor) 4 
FRLP + Homologous to angiogenin and RNase A 1 
XT2 + 58% identical to human cathepsin L 1 
EGl + Heterogeneous ribonucleoprotein 2 
EG3 + RNA-binding protein 1 
EG4 + Novel 96 kDa protein 1 
EG5 Cytoplasmic tyrosine kinase FER 1 
tively). To test the dependence on expression of the FGF 
receptor, plasmid DNA in each transformant was rescued 
and retransformed into control yeast strains or strains ex- 
pressing the FGF receptor gene. Only one plasmid was 
found to be positive in the absence of the receptor. This 
plasmid encoded a putative tyrosine kinase homologous 
to the mouse cytoplasmic tyrosine kinase FER (for fpsl 
fes-related; Hao et al., 1989; data not shown). The other 
genes increased tyrosine phosphorylation only when the 
FGF receptor gene was coexpressed. 
Sequences of the Cloned Genes 
In the ten plasmids that activated the FGF receptor, there 
were six unique sequences (Table 1). These genes encode 
two putative secreted proteins (FRLI and FRL2), one pro- 
tease (XT2), two RNA-binding proteins (EGl and EG3), 
and one novel protein (EG4) lacking a signal sequence. 
FRLl and XT2 were isolated from the XTC library, and 
the others are from the egg library. Genes related to 
the traditional FGF gene family were not isolated in this 
screen. 
FRL-2 FRL-P 
glucose galactose 
Figure 2. The Activation of the FGF Receptor by FRL7 and FRLP in 
Yeast 
A yeast strain expressing the FGF receptor was cotransformed with 
ssFGF, FRLl, and FRLPgenesunderthecontroloftheGALl promoter. 
The transformants were streaked, and the colonies were transferred 
to two membranes and cultured on a glucose-containing or a galac- 
tose-containing plate. The membraneswere analyzed by colony immu- 
noblotting method with anti-phosphotyrosine antibody. 
Of particular interest were the two genes FRL7 and 
FRLP, which encoded polypeptides with putative signal 
sequences. Figure 2 shows that phosphotyrosine levels 
increase dramatically in yeast strains expressing the FGF 
receptor together with either FRLl or FRL2. FRLl is dis- 
tantly related to cripto, which is an EGF family member 
identified in the mouse and human (Figure 3A; Ciccodicola 
et al., 1989; Dono et al., 1993). Though the predicted 
amino acid sequence identity is very low (24%) compared 
with human and mouse cripto, the EGF motif is completely 
conserved. FRLP encodes a protein weakly homologous 
to the angiogeninlribonuclease superfamily (Figure 36; 
Beintema et al., 1988). The identity again was very low: 
21% to both bovine angiogenin (Maes et al., 1988) and 
bovine pancreatic ribonuclease A (Smyth et al., 1963; Car- 
sana et al., 1988), and 26% to the bullfrog ribonucleasel 
sialic acid-binding lectin (Titani et al., 1987). Phylogenetic 
analysis of these genes shows that FRLP does not seem 
to belong to either the angiogenin or the ribonuclease 
branches (Figure 3D). 
Both FRLl and FRLP have hydrophobic regions at the 
C-terminus; the N-terminal hydrophobic domain probably 
is the signal sequence (Figure 3C). These proteins could 
be anchored to the cell membrane by their C-termini. To 
test this possibility, we expressed these genes and the 
C-terminal deletion mutants of these genes in Xenopus 
oocytes and found that the deletion mutants were secreted 
into the media, whereas the full-length gene products were 
not (data not shown). This suggests that FRLl and FRL2 
retain an association with membranes or vesicles and that 
the C-terminal regions are required for this association. 
The XT2 sequence was found to be similar to human 
cathepsin L, sharing 58% amino acid identity in the region 
we sequenced (90 out of 155 amino acids; data not shown; 
Joseph et al., 1988; Gal and Gottesman, 1988). EGl was 
previously identified in Xenopus as a heterogeneous ribo- 
nucleoprotein (Kay et al., 1990). EG3 has an RNA recogni- 
tion motif found in many RNA-binding proteins (data not 
shown; Kim and Baker, 1993). EG4 encodes a novel 96 
kDa protein. Recently, a gene similar to EG4 was found 
by the complete sequencing of the chromosome III in 
Caenorhabditis elegans; it was designated Rl OE12.1 
(39% identity), but its function is unknown (Wilson et al., 
1994). No putative signal sequence was found in this gene 
(data not shown). 
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Figure 3. Ammo Acid Sequences of FRLl and FRLZ 
(A) Sequence alignment of FRLI with mouse cripto. Stars indicate 
identical amino acid residues. The putative signal sequence and the 
C-terminal hydrophobic region of FRLl are underlined. 
(B) Sequence alignment of FRL2 with bovine angiogenin and pancre- 
atic ribonuclease A. Asterisks indicate amino acid residues identical 
among the three. The putative signal sequence and the C-terminal 
hydrophobic region of FRLZ are underlined. 
(C) Hydrophobicity plots of FRLI and FRL2 (Kyte and Doolittle, 1982). 
(D) Phylogenetic analysis of FRL2 and some of the angiogeninlribo- 
nuclease family members: human angiogenin (Kurachi et al., 1985), 
mouse angiogenin (Bond and Vallee, 1990) rabbit angiogenin (Bond 
et al., 1993) bovine angiogenin (Maes et al., 1988) mouse ribo- 
nuclease A (Schuller et al., 1990) bovine ribonuclease A (Carsana et 
al., 1988), and bullfrog ribonuclease (Titani et al., 1987). 
FRLl and FRL2 Activate the FGF Receptor 
in Xenopus Oocytes 
Since FRLl and FRL2 were potential ligands for the FGF 
receptor, we tested whether they could also activate the 
FGF receptor expressed in higher eukaryotic cells. Since it 
is known that the activation of the FGF receptor in Xenopus 
oocytes is linked to a rapid Ca2+ release from internal 
stores (Johnson et al., 1990; Musci et al., 1990), we per- 
formed a Ca’+ release assay with Xenopus oocytes. The 
conventional way to measure agonist stimulation of recep- 
tors that have been expressed in Xenopus oocytes is to 
Figure 4. The Activation of the FGF Receptor in Xenopus Oocytes by 
FRLI and FRL2 
Indicated RNAs were transcribed in vitro and injected into oocytes. 
After 48 hr of incubation, oocytes were labeled with Wa2+ for 3 hr, 
and released Ca2+ from oocytes was measured over 10 min. 
add soluble ligand to the culture media and then assay 
release of %a’+. We have not succeeded in obtaining 
active purified preparations of FRLl and FRL2 proteins 
in soluble form. Instead, we performed the calcium release 
assays under conditions of continuous ligand exposure 
by coexpressing the ligand and receptor in the same cell. 
The mRNAs for FRLl and FRLP were coinjected with FGF 
receptor mRNA into oocytes, and the basal level of Ca2+ 
efflux was measured. We have found this assay to be 
accurate and highly reproducible. As shown in Figure 4, 
we found that coinjection of FGF and FGF receptor 
mRNAs increased Ca*+ release to a level 3-fold higher 
than that for the injection of FGF receptor message alone. 
Coinjection of FM7 and FRL2 mRNAs with the FGF recep- 
tor mRNA increased Ca*+ release 2-fold and 2.5fold, re- 
spectively. FM7 or FRL2 mRNA alone did not increase 
Ca*+ release. To test whether the stimulation of the Ca*+ 
release by FRLl and FRL2 was FGF receptor-specific, 
Xenopus platelet-derived growth factor (PDGF) receptor 
was coexpressed with FRLl and FRLP in oocytes. There 
was no increase in basal Ca*+ release by FRLl or FRL2 
in the oocytes expressing the PDGF receptor (data not 
shown). These results suggest that FRLI and FRLP can 
work as activators of the FGF receptor in oocytes as well 
as in yeast cells. 
FRL2 Binds to the Extracellular Domain of the FGF 
Receptor In Vitro 
To test whether FRLl and FRL2 bind directly to FGF 
receptor, we constructed a plasmid (XFR-AP) in which 
the extracellular domain of Xenopus FGF receptor 1 was 
fused to alkaline phosphatase (AP). This plasmid was 
transfected into COS cells, and the secreted fusion protein 
was precipitated with anti-AP antibodies and protein A- 
Sepharose beads. The beads were mixed with in vitro 
translated FRLl or FRL2 proteins, which had been sol- 
ubilized with Triton X-100, cross-linked with 3,3’-dithiobis 
(sulfosuccinimidylpropionate) (DTSSP), and washed. The 
cross-link was cleaved by 2-mercaptoethanol treatment 
and boiling. As shown in Figure 5, FRL2 was coprecip- 
itated with the receptor protein. The level of FRL2 that 
was immunoprecipitated increased 4-fold as compared 
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Figure 5. FRLP Binding to the FGF Receptor 
The fusion protein XFR-AP, composed of the extracellular domain of 
the FGF receptor and alkaline phosphatase, was produced in COS 
ceils. %-labeled FRL2 protein synthesized in the reticulocyte lysate 
was mixed with the XFR-AP in the presence or absence of unlabeled 
FGF. The proteins precipitated with anti-alkaline phosphatase anti- 
body were analyzed by autoradiography. The vector-transfected COS 
cells was used as a control (vector). The receptor brings down the 18 
kDa ligand at a level of 3.9x over background. Excess cold FGF 
reduces this to 1.9x over background. 
with the vector alone. Binding was completely competed 
by unlabeled FGF. These results indicate that FRL2 binds 
to the extracellular domain of the FGF receptor, and that 
FGF and FRL2 share a common binding site on the FGF 
receptor. We were unable to coprecipitate FRLl with the 
same binding assay (data not shown). 
FRLl and FRL2 Induce Mesoderm through 
the FGF Receptor Signaling Pathway in Animal 
Cap Explants from Xenopus Embryos 
It is known that exposure to FGF and other related growth 
factors induces mesoderm in animal caps isolated from 
Xenopus embryos (Kimelman and Kirschner, 1987; Slack 
et al., 1987; lsaacs et al., 1992). We tested whether FRLl 
and FRL2 might also be capable of inducing mesoderm 
through activation of the FGF receptor. We injected mRNA 
encoding FRLl and FRL2 into both blastomeres of 2-cell 
embryos, isolated the animal caps at stage 8, and incu- 
bated them until sibling embryos had reached stage 20. 
Uninjected caps rounded up, giving the uninduced pheno- 
type of epidermis. Animal caps injected with FRLI or FRLP 
RNAs exhibited striking morphological changes, with 
FRLl-injected animal caps elongating more than FRL2- 
injected animal caps (Figure 6A). Both showed more ex- 
treme morphological responses than animal caps treated 
with FGF. 
To demonstrate that these animal caps had responded 
to the ligands by changing the state of differentiation, we 
assayed them by reverse transcription-polymerase chain 
reaction (RT-PCR) for expression of muscle actin, which is 
a mesodermal marker, and neural cell adhesion molecule 
(N-CAM), a neural marker. As shown in Figure 6B, FRL2 
induced muscle actin, but did not induce N-CAM. By con- 
trast, FRLl induced both muscle actin and N-CAM at 
higher doses of injected RNA (5 ng), but at lower doses 
(1 ng), FRLl induced only N-CAM. At 5 ng, FRL2 RNA 
was toxic. 
We tested the dependence of FRLl and FRL2 activities 
on the FGF receptor by coexpressing a dominant negative 
FGF receptor (XFD; Amaya et al., 1991). XFD is a domi- 
nant negative mutant in which almost all the cytoplasmic 
domain of the receptor is deleted; it is thought to inhibit 
the FGF receptor by forming a heterodimerwith the endog- 
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Figure 6. Effects of the Overexpression of FRLl and FRLZ on Animal 
Caps and Embryos 
(A) Morphological changes in animal caps. FRL7 RNA (5 ng) and FRLZ 
RNA (1 ng) were injected into both blastomeres at the 2-cell stage. 
Animal caps were isolated at stage 8, cultured for 20 hr at 16OC, and 
photographed. 
(6) The effect of FRLI and FRL2 on muscle actin and N-CAM expres- 
sion. Uninjected animal caps and animal caps injected with 1 ng and 
5 ng of FRLI, 5 ng of FRLl plus 1 ng of HAV@, 5 ng of FRLl plus 1 
ng of XFD, 1 ng of FRLZ RNA, 1 ng of FRLP plus 1 ng of HAVQ, or 
1 ng of FRLP plus 1 ng of XFD RNA were cultured at 16OC for 20 hr. 
RNA was isolated, and induction of muscle actin (m. actin) and N-CAM 
genes was assayed by RT-PCR. EFl o was used as an internal control. 
(C)Common phenotypes of the tailbud stage embryos overexpressing 
FRLl and FRLP. FRLi or FRL2 RNA (1 ng) was injected into both 
blastomeres at the 2-cell stage. The left side is anterior. 
enous FGF receptor. As a control in these experiments, 
we used HAV@, which is a mutated form of XFD with a 
deletion of three amino acids in its extracellular domain; 
HAV@ does not inhibit the activation of the FGF receptor 
by FGF (Byers et al., 1992; Amaya et al., 1993). mRNA 
encoding XFD or HAV@ mutants was coexpressed with 
FRLl or FRL2 in animal caps, and the induction of muscle 
actin and N-CAM genes was assayed by RT-PCR. Sur- 
prisingly, as shown in Figure 6B, the induction of muscle 
actin by FRLl was inhibited by both XFD and HAV@. Simi- 
larly to FGF, the induction by FRL2 was inhibited by XFD 
but not by HAV@. Inhibition of both FRLl and FRL2 by 
XFD indicates that the activation of the FGF receptor is 
required for the function of FRLl and FRL2. This strongly 
suggests that FRLl and FRL2 bind to the extracellular 
domain of the dominant negative receptor and form a het- 
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Figure 7. The Paracrine Signaling Assay 
(A) The procedure. mRNA encoding FRLI or FRL2 (10 ng) was injected 
into Xenopus oocytes. After 1 day of incubation, animal cap explants 
isolated from Xenopus embryos at stage 8 were grafted onto the in- 
jected or uninjected oocytes. 
(B) The effect of FRLl and FRL2 on muscle actin and N-CAM expres- 
sion. RNA was isolated from the grafted explants when the sibling 
embryos reached stage 25. Induction of muscle actin (m. actin) and 
N-CAM genes was assayed by RT-PCR. EFI a was used as an internal 
control. 
erodimer with the full-length receptor to inhibit the receptor 
activation. The differences between the response of XFD 
and HAV@ to FFiLl and both FRLP and FGF suggest possi- 
ble differences in the interactions of these ligands with 
the extracellular domain of the FGF receptor. 
FRLI and FRL2 Can Act in a 
Non-Cell-Autonomous Manner 
To test whether FRLl and FRL2 act as intercellular signal- 
ing molecules, we have employed a paracrine signaling 
assay developed by Lustig and Kirschner (1995; Figure 
7A). In this assay, mRNA encoding FRLl or FRL2 was 
injected into oocytes and cultured for 1 day, after which 
animal caps from stage 8 embryos were grafted onto the 
oocytes. The animal caps were harvested when the sibling 
embryos reached stage 25 and were analyzed by RT- 
PCR. If the proteins act intercellularly, the proteins pro- 
duced in oocytes are expected to activate the receptors of 
the grafted tissues, resulting in the induction of the muscle 
actin, N-CAM genes, or both. As shown in Figure 78, both 
FRLl and FRL2 expressed in oocytes induced muscle 
actin and N-CAM in the animal caps. This induction was 
comparable to that for whole embryos when normalized for 
elongation factor 1 a (EFl a). This result strongly suggests 
that FRLl and FRL2 can act in a non-cell-autonomous 
manner. 
Tail-like Appendages from the Ectopic Expression 
of FRL1 
To investigate the activity of FRLl and FRLP in em- 
bryogenesis, mRNAs encoding these proteins were in- 
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Figure 8. The Temporal and Spatial Expression of FRL7 and FRLP 
Genes during Embryogenesis 
(A) Temporal expression. RNA was isolated from unfertilized eggs and 
the indicated stages of embryos. The expression of the FRLl and FRLP 
genes was assayed by RT-PCR. Ornithine decarboxylase (ODC) is 
present as an internal control. 
(6) Spatial expression. Stage 10 embryos were dissected into the dor- 
sal half (Dr) and the ventral half (Vn), or into the vegetal half including 
the marginal zone (Vg) and the animal half (An), and RNA was isolated 
from these tissues or from stage 10 embryos (Em). The expression 
of the FRLl gene was assayed by RT-PCR. goosecoid (gsc) is known 
to be expressed in the dorsal marginal zone (Cho et al., 1991). EFlu 
is a ubquitously expressed control (Krieg et al., 1989). 
(C) Whole-mount in situ hybridization in the tailbud stage embryo of 
FRLZ RNA. Purple staining indicates the localization of the antisense 
FRLZ probe. 
jetted into 2-cell embryos, and the phenotype was ob- 
served. As shown in Figure 6C, a common phenotype in 
both FRL7-injected and FRL2-injected embryos was re- 
duced anterior head morphology. Embryos without eyes, 
cement gland, or both were often found (11 out of 30 em- 
bryos injected with 1 ng of FRL7 and 11 out of 32 embryos 
injected with FRLP RNA at 2-cell stage). In addition, FRL7 
induced tail-like appendages (11 out of 30 embryos). At 
tadpole stage, a fin and melanocytes were formed, but 
neither notochord nor somites could be identified in these 
appendages by immunohistochemistry (data not shown). 
The FRLP-injected embryos showed severe gastrulation 
defects as well as head defects. The head defect pheno- 
type suggests that ectopic expression of FRLl and FRL2 
might cause posteriorization of anterior tissue, or loss of 
anteriorization. 
The Temporal and Spatial Expression Pattern 
of FRLI and FRLP in Xenopus Embryo 
The temporal expression patterns of FRL7 and FRL2 were 
mapped with RT-PCR, using ornitihine decarboxylase as 
an internal standard. As shown in Figure 8A, both FRL7 
and FRLP mRNAs were of low abundance maternally, but 
were clearly detected by stage 10. The FRLP transcript 
gradually increased during embryogenesis through stage 
38, whereas the FRL7 transcript was detectable only dur- 
ing gastrula stages and disappeared rapidly at early neu- 
rula stage. 
The spatial distribution of FRL7 expression was mapped 
with whole-mount in situ hybridization on gastrula stage 
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embryos. Expression was detected throuighout the em- 
bryo at gastrula stage (data not shown). When we dis- 
sected embryos into dorsal and ventral or animal and veg- 
etal pieces at gastrula stage, we found broad and uniform 
expression of FRL7 by RT-PCR, confirmiing the lack of 
localization by in situ hybridization (Figure 8B). As a con- 
trol, we found goosecoid expression limited to the dorsal 
lip, and EFla uniformly expressed. In situ hybridization 
of FRLP at tailbud stage shows expression in somites, otic 
vesicles, brain, eyes, cement gland, and visceral arches, 
suggesting that FRl.2 might be involved in the develop- 
ment of these tissues (Figure 8C). 
Discussion 
There are several transmembrane tyrosine kinase recep- 
tors known to be expressed at gastrula and neurula stage 
in Xenopus embryos, which suggests that several undis- 
covered ligands might be present that would play a role 
in early patterning and tissue differentiation To identify 
these molecules, we have developed a functional assay 
in yeast for ligands for tyrosine kinase receptors. Initially 
we demonstrated that we can reproduce the activation of 
the kinase by coexpression of the receptor and ligand by 
use of the FGF receptor and FGF2. We tested this assay 
on two Xenopus cDNA libraries and identified two novel 
secreted proteins, FRLl and FRLP, that activate the FGF 
receptor in the yeast assay. Surprisingly, lthese ligands 
are not members of the homologous class of FGF ligands 
and therefore constitute putative novel extracellular acti- 
vators of the FGF receptor. 
Several lines of evidence suggest that FRLl and FRLP 
can activate the FGF receptor extracellularly, although 
proof that the FGF receptor is the appropriat’e receptor for 
these or any of the FGF family of ligands is slill inferential. 
In addition to the yeast assay, both of these lllgands stimu- 
late calcium release in Xenopus oocytes in the presence 
of a functional FGF receptor. The paracrine assay shown 
in Figure 7 shows that both FRLI and FRL2 can be ex- 
pressed in one cell (the oocyte) and act on another (animal 
caps); hence, FRLl and FRL2 can act in a non-cell- 
autonomous manner. 
In the cake of FRL2, we were able to demonstrate that 
the ligand binds to the extracellular domain of the FGF 
receptor and that this binding can be competed by FGFP. 
Our inability to demonstrate this interaction with FRLl 
could be due to weaker affinity or lack of activity of the 
FRLl in the presence of the detergents needed to solubi- 
lize it. 
Further evidence that FRLl and FRL2 acts through the 
FGF receptor has come from induction assays in frog em- 
bryos. Both of these molecules gave potent and interesting 
biological effects (discussed below), and these effects, 
which include expression of muscle actin and morphologi- 
cal changes, were completely blocked by c’oexpression 
of the dominant negative mutant of the FGF receptor, XFD. 
Formally, these experiments show that the biological ef- 
fects of FRLl and FRL2 require FGF signaling, but do not 
prove that these ligands act directly on the FGF pathway. 
FRLl and FRLP might stimulate production Nor secretion 
of endogenous FGF molecules in oocytes or anirnal caps, 
or they might stimulate both activities. Indeed, it is known 
thatXFD inhibitsthe mesoderm induction byactivin, which 
does not interact with the FGF receptor (LaBonne and 
Whitman, 1994; Cornell and Kimelman, 1994). However, 
one unusual experimental result suggests that this is not 
the case for FRLl. Its ability to induce muscle actin was 
inhibited, and its ability to induce N-CAM was partially 
inhibited not only by XFD, but also by a mutant form of 
the dominant negative inhibitor, HAV@, that does not in- 
hibit FGFfunction (Byers et al., 1992, Amaya et al., 1993). 
This indicates that FRLl does not function through endog- 
enous FGF and may suggest that FRLl interacts with dif- 
ferent binding determinants in the FGF receptor than does 
FRL2 or FGF. Taken together, these data suggest a direct 
interaction for both FRLl and FRL2 with the FGF receptor 
but provide strict proof only for FRLP, where direct and 
FGF-competable binding with the extracellular domain 
can be demonstrated. 
Finding a new member of the FGF family of ligands 
would be interesting but not surprising. Finding two novel 
putative ligands with no homology to the FGF familly mem- 
bers is more unusual, since in general, receptor tyrosine 
kinases have been thought to interact with specific ligand 
family members. However, FGF receptor family members 
differ in their extracellular domains, which could be the 
basis of differences in receptor binding. Indeed, we have 
found that the FGF receptor 4 from Xenopus can be acti- 
vated in the yeast assay with FGFP but not with FFlLl and 
FRL2 (N.K., unpublished data), while the FGF receptor 1 
can be activated by all three ligands. Interactions of a 
receptor with more than one ligand family are not unprece- 
dented. For example, the insulin-like growth factor (IGF)-II 
receptor interacts not only with IGF-II but also with man- 
nose8-phosphate, and IGF-II also interacts with the IGF-I 
receptor (Morgan et al., 1987; Rechler et al., 1980). 
The Nature of FRLI and FRLP and Their Role 
in Development 
FRLl contains an EGF motif, with only 24% identity to 
mouse cripto. In the mouse embryo, cripto is expressed 
in the primitive streak and mesodermal cells, and llater in 
the heart (Dono et al., 1993), suggesting that cripto might 
be involved in mesoderm formation. In Xenopui, FRLl is 
expressed throughout gastrulation and early neurulation, 
a period of about 4 or 5 hr, and is not localized. FRLl 
could be regulated posttransriptionally or posttransla- 
tionally. 
FRLl shows different inductive effects compared with 
those of FGFor FRLP. A high dose of FRL7 mRNA induced 
both muscle actin and N-CAM, while a lower dose induced 
only N-CAM, but not muscle actin. Hence, FRLl can in- 
duce neural tissue without inducing appreciable meso- 
derm or at least muscle in this assay. Though other meso- 
derm inducers, such as activin, can also induce rneural 
tissues, this is thought to be an indirect induction meldiated 
by the dorsal mesoderm induced by activin. 
FRL2 shows no homology to typical FGF family mem- 
bers but is distantly related to the ribonuclease/angialgenin 
family (identities of 21%-26%). These molecules share 
Cdl 
628 
conserved cysteine positions and a conserved histidine 
bounded by valine and phenylalanine in the C-terminus. 
Angiogenin has strong angiogenic activity, which is also 
true of FGF (Folkman and Klagsburn, 1987; Risau, 1990). 
There is no known receptor for angiogenin, and it is tempt- 
ing to speculate that angiogenin, like FRLP, might activate 
a member of the FGF family of receptors, rationalizing 
why it is effective as an angiogenic agent. FM2 mRNA 
was detected at gastrula stage and gradually increased 
through tadpole stage. It is expressed broadly in somites, 
nervous system, eyes, cement gland, and visceral arches, 
where the FGF receptors 1 and 4 are expressed (Brandli 
and Kirschner, 1995). 
The Yeast Assay for Tyrosine Kinase Function 
In the initial studies of the FGF receptor and basic FGF, 
we found that the receptor was activated only if FGF pos- 
sessed a signal sequence (ssFGF). We did not determine 
cytological localization of the receptor or the ligand. How- 
ever, ssFGF expressed in yeast was not detected in the 
medium by immunoblotting with anti-FGF antibody, sug- 
gesting that the FGF receptor might be activated in intra- 
cellular compartments. This property made the assay 
strictly cell autonomous. Theoretically, there is no reason 
why ligands and receptors could not meet in intracellular 
vesicles and signal in the cytoplasm. In mammalian cells, 
the v-sis oncogene, a dimer of PDGF 0 chains, has been 
shown to transform cells without secretion by activating 
the PDGF receptor in intracellular compartments (Keating 
and Williams, 1988; Westermark and Heldin, 1991). The 
receptor may be activated by FGF in yeast and higher 
organisms in the similar manner, where activation of the 
receptor could occur by an encounter with the ligand in 
the endoplasmic reticulum, Golgi, or other vesicular com- 
partment. 
To our surprise, the initial screen for FGF ligands did 
not produce typical FGF ligands, despite the demonstra- 
tion that FGFP is active in the assay. Part of that reason 
may be that the level of maternal mRNA encoding FGF 
is greatly reduced after oocyte maturation (Kimelman and 
Kirschner, 1989), and the other FGF forms may be quite 
rare. It might be that the signal sequence of these FGFs 
might not be functional in yeast. Finally, it could be that 
owing to glycosylation differences, FGFs synthesized in 
yeast may have low affinities for the receptor. Three other 
proteins activated the receptor. There are avariety of ways 
a protease and RNA binding-proteins might affect the level 
of expression or its function. 
It has become increasingly clear that several signaling 
systems operate in the early embryo to specify the pattern 
and differentiation of tissues. The existence of large fami- 
lies of receptors and ligands is not likely to reflect simply 
redundancy but different signals for different processes. 
In general, it is not possible to identify which ligand and 
receptor interact in vivo. The discovery of novel FGF recep- 
tor ligands along with the multiplicity of FGF-type receptors 
intensifies this issue. The results of this investigation sug- 
gest that receptors may be even more promiscuous than 
simply operating within a single family of ligands. To iden- 
tify these ligands, screening by structural homology might 
need to be augmented by independent screens based on 
functional assays. 
Experimental Procedures 
Yeast Strain and Plasmids 
The yeast (S. cerevisiae) strain used in this study was PSY315 (Mata, 
/euZ-3.122, ura3-52, his3-d200, /ysZ-802). 
The vector plasmids pTS210 and pTS249 carry URA3 and LEUP, 
respectively, and both carrythe CfN4, GAL1 promoter and ACT7 termi- 
nator (gifts from Dr. T. Stearns, Stanford University). pKNA1 is the 
same as pTS249, except that the GAL promoter is replaced with ACT7 
promoter. The promoter of ACT1 (Gallwitz et al., 1981) was cloned by 
PCR using yeast genomic DNA as a template. The length of the frag 
ment is 678 bp. 
Two plasmids for expression of Xenopus FGF2 in yeast were con- 
structed: one plasmid was constructed by cloning FGF2 into pTS210 
(pFGF), and the other plasmid is identical to the first one, except that 
a signal sequence of S. cerevisiae SUC2 (Carlson et al., 1983) was 
inserted at the initiation codon of the FGF2 gene (pssFGF). For FGF 
receptor expression, the Xenopus FGF receptor 1 gene (Musci et al., 
1990) was subcloned into pTS249 and pKNA1 (pG-FGFR and PA- 
FGFR, respectively). 
The full-length construct XFR and the dominant negative construct 
XFD of the FGF receptor have been described by Amaya et al. (1991). 
The deleted mutant construct HAV@ has been described by Amaya 
et al. (1993). 
The vector plasmid pCS2+ (Turner and Weintraub, 1994) was used 
for in vitro transcription of the FRL7 and FRLP genes. The coding 
regions were amplified and tagged with the FLAG sequence (Hopp 
et al., 1986) at the C-terminus by PCR and inserted to pCSP+. 
lmmunoblotting 
Anti-phosphotyrosine antibody 4G IO was purchased from Upstate Bio- 
technology, Incorporated. Anti-alkaline phosphatase was purchased 
from Medix Biotech. Anti-FLAG M2 antibody was purchased from Ko- 
dak. Polyclonal rabbit serum against FGF2 was raised against bacteri- 
ally expressed Xenopus FGF2 protein (Kimelman et al., 1988). 
For colony immunoblotting, we followed the procedure described 
by Lyons and Nelson (1984). Colonies were transferred onto two nitro- 
cellulose membranes (Millipore HATF 082) and incubated on SD and 
SG plates overnight at 30%. The cells were lysed with 0.1% SDS, 
0.2 M NaOH, 35 mM DTT. Chemiluminescence reagents (ECL, Amer- 
sham) were used for detection. 
cDNA Libraries 
Two cDNA libraries, the egg and embryo library and the XTC library, 
were used. The vector plasmid of the cDNA library was hYES (Elledge 
et al., 1991). 
cDNA for the XTC library was isolated from XTC cells and XTC 
cells treated with 100 nglml nocodazole for 24 hr. Untreated and noco- 
dazole-treated mRNAs were used in the ratio 4:l. cDNA for the egg 
and embryo library was isolated from eggs, 10 hr embryos (gastrula), 
and 10 hr embryos treated with IO pglml nocodazole between 8 and 
IO hr. mRNA from each was used in the ratio 1:3:1. 
Assays 
Ca2+ Release Assay 
We followed the method previously described by Musci et al. (1990) 
and Amaya et al. (1991). Injected oocytes were cultured at 16% for 
48 hr and washed in Ca2+-free solution. %a*+ (Amersham) was loaded 
for 3 hr and then washed extensively. The radioactivity released for 
the first 10 min was counted. 
in Vitro Binding Assay 
A DNA fragment encoding the extracellular domain of the FGF receptor 
(from Met-l to Glu-372) was fused to the human alkaline phosphatase 
gene (Flanagan and Leder, 1990). COS cells were transiently transfected 
with the plasmid by the calcium phosphate method. The fusion protein 
was precipitated by anti-alkaline phosphatase antibody (Medix Bio- 
tech) and protein A-Sepharose (Pierce). [“Slmethionine-labeled FRLI 
and FRL2 proteins were synthesized in reticulocyte lysate with canine 
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pancreatic microsomal membranes (Promega). PEtS (10 vol), 0.5% 
Triton X-100 was added and mixed to the receptor-clonjugated Sepha- 
rose described above. To test the competition with FGF for binding 
to the receptor, 1 pglml of bacterially produced Xenopus FGF2 protein 
was added. After overnight incubation at 4”C, 2 mM of DTSSP (Pierce) 
was added and incubated for 1 hr. The Sepharose beads were washed 
four times in TBS, 0.5% Triton X-100. 
Animal Cap Assay 
RNA was injected into both blastomeres at the 2-cell stage. Animal 
caps were isolated at stage 8 (Nieuwkoop and Faber, 1994), incubated 
in 1 x MMR at 16OC until sibling embryos reached stage20, and then 
frozen for the RNA analysis. 
RT-PCR 
RT-PCR was carried out as described (Rupp and Weintraub, 1991; 
Wilson and Melton, 1994; Lustig and Kirschner, 1995). The primer 
sequences used for analysis of EFl a, goosecoid, N-CAM, and muscle 
actin were as described (Hemmati-Erivanlou et al., 1994; Hemmati- 
Brivanlou and Melton, 1994). The primer sequences for FRLl are 5’- 
ATGCAGTTTTTAAGATTT-3’ and 5’-TTAAAGTCCAATATTCAG-3’. 
The sequences for FRLP are 5’-ATGCTTGACATTATGGTG-3’ and 5’- 
TTATCTCATAGCAGGGAG-3’. The sequences for ODC are 5’-AATG- 
GATTTCAGAGACCA-3’ and S-CCAAGGCTAAAGTTGCAG3’ (Bas- 
sez et al., 1990). 
Paracrine Signaling Assay 
The paracrine signaling assay was carried out as described (Lustig 
and Kirschner, 1995). 
Whole.Mount In Situ Hybridization 
The procedure for the whole mount was carried out as described (Har- 
land, 1991). The antisense strands of the FRLI and FR1-2coding region 
were used for the probes. 
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